Live Breaking News & Updates on Sarah noonberg

Stay informed with the latest breaking news from Sarah noonberg on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Sarah noonberg and stay connected to the pulse of your community

Metagenomi Reports Business Updates and Full Year 2023 Financial Results

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman primate durability data in 2H 2024 Proof of...

Brianc-thomas , Sarah-noonberg , Luis-borges , Simon-harnest , Pamela-wapnick , Ashlye-hodge , Metagenomi-inc , Securities-exchange , Technology-platform , Nasdaq , Development-candidate

Metagenomi Reports Business Updates and Full Year 2023

Demonstrated nonhuman primate proof of concept in Hemophilia A program; progressing towards Development Candidate nomination by mid-year; 12-month nonhuman...

Sarah-noonberg , Luis-borges , Pamela-wapnick , Ashlye-hodge , Simon-harnest , Brianc-thomas , Technology-platform , Nasdaq , Metagenomi-inc , Securities-exchange , Development-candidate

Protagonist Therapeutics, Inc. Announces Retirement of Sarah Noonberg as Director

Protagonist Therapeutics, Inc. announced that Sarah Noonberg, M.D., Ph.D. did not stand for re-election as Director at the Annual Meeting of Stockholders on May 25, 2023. The Company has a vacancy on...

Sarah-noonberg , Audit-committee , Protagonist-therapeutics-inc , Protagonist-therapeutics , Annual-meeting , Markets ,

Metagenomi's Gene-Editing Palette Enables Plug-and-play Pipeline

Metagenomi's gene-editing toolbox now includes CRISPR associated transposase (CAST) systems and a novel type V CRISPR system.

Simon-harnest , Sam-sternberg , Sarah-noonberg , Wild-west ,

ASGCT News: Metagenomi Swiftly Variegates Gene-Editing Palatte

Metagenomi's gene-editing toolbox now includes CRISPR associated transposase (CAST) systems and a novel type V CRISPR system.

Sam-sternberg , Sarah-noonberg , Simon-harnest , Wild-west ,

Marinus Pharma (MRNS) Appoints Sarah Noonberg to its Board

Marinus Pharma (MRNS) Appoints Sarah Noonberg to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

California , United-states , Berkeley , San-francisco , Sarah-noonberg , Prothena-biosciences , Sasha-damouni-ellis , Scott-braunstein , Marinus-pharmaceuticals-inc , Nasdaq , Corporate-affairs-investor-relations , Marinus-pharmaceuticals

Ballet After Dark wins $25K prize at Social Innovation Lab Innovators' Showcase

A student-led nonprofit organization, which won the $25,000 Cohort Prize, was one of 10 cohort teams who presented their ventures to community members and potential funders at the April showcase

Charles-homcy , Jessica-waite , Mary-miller , Tyde-courtney-edwards , Mike-brooks , Bydanny-jacobspublished , Sarah-noonberg , Johns-hopkins , Johns-hopkins-technology-ventures , Equine-center , Innovation-lab , After-dark

Maze Therapeutics initiates dosing in Phase I Pompe disease therapy trial

Maze has commenced participant dosing in its Phase I clinical trial of oral glycogen synthase (GYS1) inhibitor, MZE001, to treat Pompe diseas

Sarah-noonberg , Life-sciences-companies , Translation-services-for , Maze-therapeutics , Cellular-immune , Life-sciences , Key-challenges , Global-clinical-trial ,

Shasqi Announces Strategic Advisors as it Advances Click-Chemistry Based Treatments for Cancer

Posted on
524
Shasqi, a clinical-stage biotechnology company developing precision activated oncology therapeutics with its proprietary Click Activated Protodrugs Against Cancer (CAPAC
TM) platform, announced today the members of its strategic advisory board, which bring a range of expertise to the company including corporate strategy, clinical development, cellular biology, and cancer therapeutics.
“Shasqi has made important progress during the last year with the initiation of our phase 1 clinical trial of SQ3370 and the advancement of our CAPAC drug development platform we’re preparing for the next phase of our growth,” said José M. Mejía Oneto, M.D., Ph.D., Founder and CEO of Shasqi. “We’ve deliberately selected and cultivated a team of strategic advisors with the skills, expertise and experience to help us navigate through the opportunities ahead of us and, ultimately, position us to benefit as many people living with cancer as possible.”

Oregon , United-states , United-kingdom , Stanford , Leicestershire , British , Lawrenced-mayer , Nina-shapiro , Cory-tromblee , Williamj-rieflin , Glenn-prestwich , Pamelam-klein